Ocugen’s model fair value holds at US$11.43 per share, with no change to the underlying price target despite fresh clinical and financing updates. That stability reflects a cautious analyst stance ...

The average one-year price target for Ocugen (NasdaqCM:OCGN) has been revised to $8.36 / share. This is an increase of 26.15% from the prior estimate of $6.63 dated September 27, 2025. The price ...

) has been revised to $11.37 / share. This is an increase of 11.43% from the prior estimate of $10.20 dated March 25, 2026. The price target is an average of many targets provided by analysts. The ...

Investors might want to bet on Ocugen (OCGN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

Ocugen Inc. (NASDAQ:OCGN) is one of the popular penny stocks on Robinhood to buy. On March 2, Ocugen, Inc. (NASDAQ:OCGN) announced the completion of patient enrollment for its Phase 3 liMeliGhT ...

Ocugen OCGN is advancing a late-stage ophthalmology pipeline built around one-time gene therapies for retinal diseases with ...

Ocugen, Inc. (NASDAQ:OCGN) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 17, 2026, Canaccord initiated coverage of Ocugen, Inc. (NASDAQ:OCGN) with a Buy rating and a $12 price ...

The last time I spoke about Ocugen (OCGN) it was with respect to a Seeking Alpha article entitled "Ocugen: Two Gene Therapy Data Readouts In 2024 to Drive Value". With respect to this article, I ...

) has been revised to $8.36 / share. This is an increase of 26.15% from the prior estimate of $6.63 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...